Finanzen von Inhibikase Therapeutics Inc (IKT)IKTInhibikase Therapeutics Inc

Evaluating the bottom line, Inhibikase Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -51.96%, provide a clear picture of how effectively IKT converts its operational activities into shareholder value.

In the context of the broader market, IKT competes directly with industry leaders such as ABEO and STRO. With a market capitalization of $344.65M, it holds a significant position in the sector. When comparing efficiency, IKT's gross margin of N/A stands against ABEO's 63.30% and STRO's 100.00%. Such benchmarking helps identify whether Inhibikase Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Inhibikase has shown a significant increase in cash reserves, rising from $97.5 million in 2024 to $178.8 million in 2025, enhancing its financial flexibility. Despite this, the company has been facing consistent net losses, with Q2 2026 showing a loss of -$19.59 million.